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Background: Arteriovenous malformations (AVMs) are a type of high-flow vascular malformations that most
commonly occurs in the head and neck. They are present at birth but are usually clinically asymptomatic until later
in life. The pathogenesis of AVMs remains unclear and therapeutic approaches to AVMs are unsatisfied. In order to
provide a tool for studying the pathogenesis and therapies of this disease, we established and studied a xenograft
animal model of human AVMs.
Methods: Fresh human AVMs specimens harvested from 4 patients were sectioned (5x5x5 mm) and xenografted
subcutaneously in 5 immunologically naïve nude mice (Athymic Nude-Foxn1nu). Each mouse had four pieces
specimens in four quadrants along the back. The grafts were observed weekly for volume, color and texture. The
grafts were harvested at every 30 days intervals for histologic examination. All grafts (n = 20) were sectioned and
stained for hematoxylin and eosin (H&E). Comparative pathologic evaluation of the grafts and native AVMs were
performed by two blinded pathologists. Immunohistochemical examination of human-specific nuclear antigen,
vascular endothelial growth factor receptor-2 (VEGFR-2) and Ki-67 was performed.
Results: Clinical characteristics and pathologic diagnosis of native human derived AVMs were confirmed. 85%
(n = 17) of AVM xenografts survived although the sizes decreased after implantation. Histological examination
demonstrated numerous small and medium-size vessels and revealed structural characteristics matching the native
AVMs tissue.76.5% (n = 13) of the surviving xenografts were positive for Ki-67 and human-specific nuclear antigen
suggesting survival of the human derived tissue, 52.9% (n = 9) were positive for VEGFR-2.
Conclusions: This preliminary xenograft animal model suggests that AVMs can survive in the nude mouse. The
presence of human-specific nuclear antigen, VEGFR-2, and Ki-67 demonstrates the stability of native tissue qualities
within the xenografts.
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Arteriovenous malformations (AVMs) are a type of
high-flow vascular malformations [1,2]. They are usually
congenital and clinically asymptomatic until later in life.
AVMs are known to arise from a cluster of aberrant
arteriovenous shunts. They are comprised of numerous
hypertrophic tortuous arteries that drain into arterialized
veins forming a vascular nidus, which thought to have* Correspondence: gtrichter@uams.edu
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stated.growth potential [3-5]. Although, AVMs are thought to
grow synchronously with a child’s development, as a result
of hormonal changes, inappropriate therapy and trauma,
dramatic enlargement can occur [6-10]. This rapid and
progressive enlargement will cause dysfunction, disfigure
and even become a life-threatening problem [6,7,11]. Vari-
ous therapeutic options have been used for AVMs, includ-
ing surgical excision, surgical ligation of feeding arteries,
selective vessel embolization, sclerotherapy and laser ther-
apy. But none of the current therapeutic modalities is ideal
for AVMs [6,7].
Despite many years of research, the etiology and
pathogenesis of AVMs is not yet clear and the current. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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this study, with the aim of developing a reproducible
model of AVMs and understanding the pathogenesis and
exploring novel therapies of AVMs, we herein present
preliminary results of an animal model of human AVMs
by using human AVM tissue xenografting.Methods
Specimens
This study was approved by the Institutional Review
Board (University of Arkansas for Medical Sciences) and
Institutional Animal Care and Use Committee (University
of Arkansas for Medical Sciences). Fresh surgical speci-
mens of head and neck subcutaneous AVMs were ob-
tained from 4 patients (43-year-old female, 41-year-old
female, 30-year-old male and 21-year-old female) with
the diagnosis confirmed via clinical, radiographic and
histologic assessment. At the time of resection, surgical
specimens were divided for xenograft implantation and
formalin fixation (10%) with paraffin embedding.Figure 1 The growth characteristics of human AVM xenografts in nud
transplantation (mean ± SD). (B) Graft appearance in the four quadrants of
days after transplantation, the grafts turn to blue discoloration and a harde
(arrows). (E) At 60th day harvest, the graft was vascular and slightly smallerThe establishment of animal model
Five female 6-to 8-week-old nude mice (Athymic
Nude-Foxn1nu; Harlan, Houston, TX) were used for
this experiment. Ketamine hydrochloride (100 mg/mL;
ButlerSchen, Dublin, OH), xylazine hydrochloride
(40 mg/mL; AnaSed, Shenandoah, IA) and phosphate-
buffered saline solution (PBS, pH 7.4; Sigma-Aldrich,
St Louis, MO) at premixed 1:1:2.3 volume ratios were
used for intraperitioneal injection anesthesia (2.22 mL/Kg)
in mice. Fresh human AVM specimens were sectioned
into approximately 5×5×5 mm pieces and inserted
subcutaneously into 4 quadrants along the back of the
nude mice. A single section was placed at 1 quadrant.
Two mice were used for placement of the sections from
the 43 year-old-patient. A total of 5 mice were used to
place 20 xenografts in this experiment.
Observation, measurement and harvesting
The xenografts were monitored for volume, color and tex-
ture at 7-day intervals throughout the period of the study.
Simultaneously, the size of each graft was recorded usinge mice. (A) The general drift of the grafts voluminal alteration after
the nude mouse back at 5 days post transplantation (arrows). (C) 18
r texture (arrows). (D) At 27 days, the grafts gradually turned purple
in size than original tissue (arrow).
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diameters (a and b). The volume (V) of grafts was esti-
mated as V = π/6[(a × b)3/2] [12]. With satisfactory
anesthesia, each graft was harvested at essentially serial
30-day intervals (30, 60, 90, and 120 days). All mice
were humanely killed after removing the final graft.
Histological analysis
All the harvested grafts were fixed in 10% neutral buff-
ered formalin and embedded in paraffin. Then four-
micrometer thickness sections were cut, deparaffinized
and stained with hematoxylin (Fisherbrand, Pittsburgh,
PA) and eosin (Thermo Fisher Scientific, Waltham, MA)
(H&E). All the slides were examined by 2 blinded patholo-
gists (CY. Fan and A.G. Sadd) experienced with vascular
anomalies (VA).
Immunohistochemistry
After deparaffinization and rehydration, the sections were
heated to 97°C for 20 minutes in a water bath in the pres-
ence of antigen retrieval solution (CITRA, pH 6.0; Invitro-
gen, Carlsbad, CA) and cooled for 30 minutes. To block
the endogenous peroxidase activity, all sections were incu-
bated with hydrogen peroxide for 10 minutes and washed
with a PBS (pH 7.4; Sigma-Aldrich, St Louis, MO). Sec-
tions were preincubated with 2% nonfat milk for 30 mi-
nutes at room temperature. Then sections were incubated
with primary Vascular endothelial growth factor receptor-
2 (VEGFR-2, rabbit anti-human polyclonal antibody;
Abcam, Cambridge, MA) at 1:200 dilution or Human-
specific nuclear antigen (mouse anti-human monoclonal
antibody; Millipore, Billerica, MA) at 1:400 dilution or
Ki-67 (rabbit anti-human monoclonal antibody; Abcam,
Cambridge, MA) at 1:100 dilution for 20 hours at 4°C.
After washing in PBS, sections were incubated in primary
antibody enhancer (Thermo Fisher Scientific, Waltham,
MA) for 10 minutes and horseradish peroxidase polymer
(Thermo Fisher Scientific, Waltham, MA) for 15 minutes
at room temperature. After washing the sections in PBS,
they were incubated with diaminobenzidine (Thermo
Fisher Scientific, Waltham, MA) for 5minutes at room
temperature. The sections were counterstained with
hematoxylin for 20 seconds. Sections were dehydrated
through graded alcohol solutions and cleaned by xy-
lene substitute. Then they were mounted with per-
mount (Thermo Fisher Scientific, Waltham, MA) and
coverslipped.
Native human AVM specimens were used as a positive
control for VEGFR-2 antibody. Human tonsil tissues
were used as a positive control for Ki-67 antibody. Un-
affected mouse skin and subcutaneous tissues were used
as the negative control for VEGFR-2 antibody. Mouse
myocardium tissues were used as the negative control
for Human-specific nuclear antigen. The staining resultswere validated by a blind review performed by 2 patholo-
gists (CY. Fan and A.G. Sadd) with extensive experience
examining VA and immunohistochemistry. A strong stain-




All nude mice survived the entire experimental protocol
until the last graft was harvested. On average, the xeno-
grafts had a small but brief growth phase until day 30–40.
Following this transition the xenografts underwent a grad-
ual decrease in size. Graft size appeared quiescent from
the 60th to 95th day after transplantation (Figure 1A, The
data were expressed as means ± SD). Before transplant,
the fresh human AVM specimens were red and consist-
ently soft in texture. After transplantation, the grafts ap-
pearance under the nude mouse skin was pink, flat and
soft until day 18 of transplantation with a shift to blue
discoloration and a harder texture (Figure 1B, C Arrow).
At 1 month, the grafts gradually turned purple (Figure 1D,
Arrow). At the date of harvest, 18 harvested grafts (90%)
were round and vascular (Figure 1E, Arrow).
Histopathology of grafted AVMs
H&E staining of the harvested xenografts sections showed
17 grafts (85%) were composed of densely packed vessels
and presence of a vascular malformation despite day of
harvest (Figure 2A, B, C). This suggest those grafts were
survived throughout the experiment.
Especially, in the center of the xenograft sections,
abundant of plump endothelial cells (ECs) with incon-
spicuous lumina were crowded together which has the
same structural characteristics of human AVM nidus
(Figure 2). While, in the peripheral area, the identification
of tortuous thick-walled arteries and veins were noted
(Figure 3A, Arrow).
Generally, tissue quality was better in younger grafts.
Thirty days after transplantation, in the center of the tis-
sue, the cellular density was highest. At 60 days after
transplantation fibrous and fat tissue was identified in the
harvested specimens, which was retained until day 120.
Although the grafts decreased in volume with time but
the densely of cells and vessels were almost maintained
(Figure 2A, B, C).
Immunohistochemistry
To verify that the AVMs in the xenograft were retained
human specimens and composed of human ECs, we per-
formed Immunohistochemistry by using Human-specific
nuclear antigen and anti-human VEGFR-2 antibody.
A total of 76.5% grafts (n = 13) were positive for Human-
specific nuclear antigen (Figure 4A) and 52.9% (n = 9) grafts
were positive for human VEGFR-2 (Figure 3A), of the
Figure 2 Histopathology of xenograft AVMs. (HE × 200). 30 days (A), 60 days (B), 90 days (C) after transplantation, abundant of plump ECs
with inconspicuous lumina were crowded together, in the center of the tissue. The densely of cells and vessels were almost maintained despite
day of harvest. ECs in the grafts which are characterized by large nuclei and scant cytoplasm, lining inconspicuous vessels can be found has the
same structural characteristics as the ECs in the pre-implanted human AVM nidus (D).
Figure 3 The immunostaining for VEGFR-2. (IHC × 200). (A) A lot of AVM “nidus” ECs in the grafts were positive for VEGFR-2. Tortuous thick-walled
arteries and veins were noted in the peripheral area (arrow). (B) The ECs in the pre-implanted human AVM “nidus” were positive for VEGFR-2. (C) The
ECs of arteries and veins in pre-implanted human AVM specimens were positive for VEGFR-2. (D) Unaffected mouse skin and subcutaneous tissues
were negative for VEGFR-2.
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Figure 4 AVM grafts immunostaining for Human-specific nuclear antigen and Ki-67. (IHC × 200). (A) Human-specific nuclear antigen was
positive in the grafts, but negative (B) in Mouse myocardium tissues. (C) Ki-67 was positive in transplanted grafts.
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specimens of AVMs were confirmed positive for VEGFR-2
immunostaining (Figure 3B, C). Unaffected mouse skin and
subcutaneous tissue was also stained and confirmed nega-
tive for VEGFR-2 (Figure 3D), and mouse myocardium was
negative for Human-specific nuclear antigen (Figure 4B).
To further examine the AVMs in the xenograft have the
potential to grow, we immunostained for Ki-67, a marker
of cellular proliferation. Of the survived xenografts, 76.5%
grafts (n = 13) were positive for Ki-67 (Figure 4C). But, the
pre-implanted human AVM tissues were confirmed nega-
tive for Ki-67 immunostaining.
Discussion
AVMs tend to progress slowly, but prior therapy, preg-
nancy or trauma may cause their rapid expansion
[6-10]. With time, AVMs will expand to excessive size
and infiltrate local tissues. This relentless growth will
cause mass effect on surrounding tissues, lead to func-
tional deficits, aesthetic impairment, long-term sequelae
and even become a life-threatening problem [6,7,11]. Un-
fortunately, current therapeutic modalities are unsatisfied;
especially many treatments have shown to stimulate the
AVMs recruitment [6,7].
Some evidence suggests that complete surgical resec-
tion with preoperative embolization has remained the
most likely chance for cure, especially in the early phase
[7,13]. But diagnosis of such lesions in the early phase is
not easy. Many AVMs are misdiagnosed as infant hem-
angiomas (IH) during infancy which will limit patient
access to appropriate therapy [7]. The problematic aspect
of these lesions has been compounded by the etiology and
pathogenesis of AVMs is poorly understood. This has led
to invalid and wrong treatment protocols [14-17]. Besides,
the research of AVMs at present mostly depends on the
study of surgical specimens. To understand development
of AVMs and improve the treatment, animal models for
the disease have to be developed.
To date, there are no animal models that truly reflect
the human AVMs. Experimental models of brain AVMshave been established in rats, cats and dogs [18-21]. Es-
pecially, rat models have been most extensively investi-
gated. It was reported that the model in rat has been
created by anastomosing the caudal end of the external
jugular vein to the side of the common carotid artery
[21]. But all these models represent Arteriovenous fistu-
lae rather than AVMs. Besides, these models were a sur-
gically created and do not contain the native human
AVM nidus [21].
Recently, Yao et al., [22] reported a very interesting
AVM model by using Mgpnull (Mgp−/−) mice. But
Matrix Gla protein (Mgp) gene deletion in mice only
formatted AVMs in lungs and kidneys. And mice that
lack of Mgp will die within two months as a result of
arterial calcification which leads to blood-vessel rupture
[23]. While, human AVMs are usually thought to be a
kind of chronic and slow development disease. More im-
portantly, these models were not developed from native
human AVMs, the ideal tissue sample for investigation
of this disease.
Previous studies have demonstrated that the IH and
lymphatic malformations, two different types of VA, can
survive in the nude mouse [24-26]. Nude mice are thymus
absent and T-cell deficient. They have the ability to receive
many different types of tissue and tumor xenografts
[27-31]. As another type of VA, we hypothesized that
AVMs may also survive in the nude mouse and likely to
retain their principal morphologic and biological proper-
ties when grafted. To test this hypothesis, we used nude
mouse as the vehicle to establish a human AVM tissue
xenografted model.
In this study we demonstrate the survival of human
AVMs in 17 of 20 (85%) xenografts harvested from 4
patients. A brief period of growth occurred early but
was not maintained as the samples became quiescent
and subsequently diminished in size over a period of
120 days. Xenografted tissue appears ideally reflective of
native AVMs at 20–30 days post transplantation. Necrosis
or tissue loss was not identified in any of the harvested
grafts. Structural characteristics of human AVMs were
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survived grafts, abundant of plump ECs with inconspicu-
ous lumina were crowded together just has the same
structure as human AVM nidus which is characterized by
large nuclei and scant cytoplasm, lining inconspicuous
vessels. And also the tortuous thick-walled arteries and
veins were found packed at the periphery of the speci-
mens. These results suggest that xenografted human AVM
tissues can survive in the athymic nude mice. However,
AVMs cannot be identified only by light microscopic def-
inition in current pathologic practice. It also needs to be
confirmed by immunostaining. But at present, no specific
markers that can labels AVM ECs and reliably diagnose
AVMs.
VEGFR-2, as the EC marker, plays a broader role in
angiogenesis. Its activity regulates endothelial cell growth,
differentiation, migration and tubulogenesis; [32] While
it has been used to identify the ECs in many studies, es-
pecially in AVMs and IH [33,34]. So, in this experiment,
we choose anti-human VEGFR-2 antibody as a marker
of AVM ECs. We have shown that, both the AVM ECs
in the grafts and in the pre-implanted human AVM
tiusses revealed strong positive staining of VEGFR-2.
While the mice skin and subcutaneous tissue were con-
firmed negative for VEGFR-2 immunostaining. To verify
that the AVMs in the mice xenografts were composed of
human ECs, we performed staining specific to human
antigens. The strong positive staining of Human-specific
nuclear antibody grafts are the majority of our samples
(76.5%). These findings indicate that the AVMs in the
mice xenografts originated from human ECs and were not
the result of infiltration by murine ECs.
AVMs are thought to have nidus, packed with immature
capillary vessels, which is the angiogenesis center of
AVMs. It has inherent growth potential and high level
of angiogenic factors [3-5]. In this research, only 52.9%
(n = 9) of implants in all the survived xenografts were
positive for VEGFR-2. While 76.5% (n = 13) of mice
xenografts have been shown originated from human.
We speculate that some specimens we have plant into
nude mouse are thin-walled small mature AVM vessels
instead of the AVM nidus.
In this research, to identify the potential presence of
proliferating cells within the xenografts, we immuno-
stained for Ki-67, a marker strictly associated with cell
proliferation [35]. Although AVMs are a slow growing
entity in humans, Ki-67 positive AVM ECs have been
documented in many studies [4,36,37]. Interestingly, we
found that 13 grafts stained positive for Ki-67, while the
original human AVM specimens were negative for Ki-67.
Also we have observed that the xenografts had a brief
growth phase until day 30–40 after transplantation. These
results may indicate that cellular proliferation is occurring
in the tissue sample following transplantation, which isconsistent with the fact that AVMs often clinically silent,
but surgery, trauma and hormonal changes may trigger
their rapid expansion [6-10].
In addition, this study had a number of limitations.
First, although the xenografts had a small but brief growth
phase, they were found to slowly but progressively de-
crease in size after day 30–40 post transplantation. One
possible explanation for this is the transplantation may
only trigger the AVMs expansion for a short phase with-
out human hormones. Second, we can not tell the original
human AVM specimens, we have plant into nude mouse,
are mature AVM vessels or the AVM nidus. Maybe the
growth of the xenografts will be sustained when they
contain dominant AVM nidus. Third, AVMs as a kind
of chronic and progressive disease, it usually tends to
progress slowly. However, the protocol of this study re-
quired that the grafts be harvested at 30 day intervals until
harvested them all (120 day max). How long these AVM
grafts can survive, and if they can be stimulated to grow,
needs further research.
Although this model may does not accurately reflect
all of the features of human AVMs, this study reveals for
the first time that human AVMs can survive in nude
mouse with structural and molecular characteristics simi-
lar to the original human specimens. This in vivo model is
unique in that the AVM lesions are able to observe by the
naked eye, and it may provide a valuable resource for
examining the pathophysiology and potential treatment.
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